|
Volumn 297, Issue 9, 2007, Pages 950-951
|
Advanced prostate cancer and postoperative radiotherapy [8]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
HORMONE;
PROSTATE SPECIFIC ANTIGEN;
ADVANCED CANCER;
CANCER MORTALITY;
CANCER PREVENTION;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
CLINICAL EFFECTIVENESS;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
FOLLOW UP;
HORMONAL THERAPY;
HUMAN;
LETTER;
METASTASIS;
POSTOPERATIVE CARE;
PRIORITY JOURNAL;
PROSTATE CANCER;
RANDOMIZED CONTROLLED TRIAL;
RISK BENEFIT ANALYSIS;
URETHRA STRICTURE;
URINE INCONTINENCE;
ADJUVANT THERAPY;
MALE;
NOTE;
PROSTATE TUMOR;
RADIOTHERAPY;
SURVIVAL;
HUMANS;
MALE;
NEOPLASM METASTASIS;
PROSTATIC NEOPLASMS;
RADIOTHERAPY;
RADIOTHERAPY, ADJUVANT;
SURVIVAL ANALYSIS;
|
EID: 33847758646
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.297.9.950-a Document Type: Letter |
Times cited : (1)
|
References (5)
|